

# Ethical Issues in Health and Health-Related Research

# Dr. J Montoya

- Advances in health research give rise to issues that challenge research ethics and the stakeholders of research
  - Data privacy
  - PHREB policies and procedures
  - HSS research ethics review
  - Balancing risks vs benefits
  - Research in older patients
  - Engaging patient and the family
- Promoting research and research ethics to larger community

## A. Data privacy in health research and clinical practice (Prof. P Sy)

	Issue	Others/ response
Privacy; Decisional privacy	Person determines extent of information communicated to others	RA 10173 Data Privacy Act 2012 – balances right to privacy and information free flow <ul style="list-style-type: none"> <li>• Safeguards in place</li> <li>• Processing of the data in research</li> </ul>
Personal information	<ul style="list-style-type: none"> <li>• Unique identifiers (e.g., iris)</li> <li>• Sensitive personal information (e.g., race, religion, gene ID, gov't ID)</li> <li>• Research data</li> <li>• Anonymized not enough</li> </ul>	<ul style="list-style-type: none"> <li>• Proportionality</li> <li>• Personal information control (processor and processing)</li> <li>• Accountability</li> <li>• Criminal liabilities for breaches</li> </ul>
Consent (e.g., purpose, length)	<ul style="list-style-type: none"> <li>• May be insufficient for protection</li> <li>• Documentation of consent</li> <li>• Below age of consent – sharing of IDs</li> </ul>	<ul style="list-style-type: none"> <li>• Transparency and data retention</li> <li>• National laws</li> </ul>
Government agencies' access	Disease registries	Re-contact

## A. Data privacy in health research and clinical practice (Prof. P Sy)

	Issue	Others/ response
Social Media (e.g. research in FB)	<ul style="list-style-type: none"> <li>• ‘Emotional proportionality (?)’</li> <li>• Nature of the contents</li> </ul>	<ul style="list-style-type: none"> <li>• Accessibility by subject to amend information</li> <li>• Limitation of use disclosure and retention</li> </ul>
Government funding	Required to make accessible	
Data	Retention Accuracy, completeness, up-to-dateness Data breaches (e.g., loss, Safeguards	Institutional purging of data  Proportionate protection
Compliance to data privacy	As above	Laws

# 1. Panel Reactors (Data Privacy)

	Dr. FM Dayrit (Academe)	Atty. AT Muyot (Legal)	Dr. AV Laudico (Registries)
<b>Challenges</b> <ul style="list-style-type: none"> <li>Control of digital data</li> <li>Insurance</li> <li>Personal data vs information known to commercial companies</li> <li>Power of the state vs the privacy of the individual</li> <li>Vulnerable groups and reliable of consent</li> <li>=&gt; Authorized body must approve the protocol <i>et al.</i></li> <li>Disease registries – data collected retrospectively</li> </ul>	Utilization of PI by companies	SMS – selling goods and commodities (via credit card Co.s)	
	What must be kept private?	Consent given by all parties concerned esp vulnerable groups – e.g. children experiencing violence at home – reliability of consent and data	
	Genetic information		
	Unknowingly provide health information that may be used for purposes not known to provider/owner	Who approves the authorization to make PI available to public	Consent <ul style="list-style-type: none"> <li>Population-based data</li> <li>Data collected after the event and consent not possible</li> </ul> Data sharing – safeguards?

# 1. Panel Reactors (Data Privacy)

Response	Dr. FM Dayrit (Academe)	Atty. AT Muyot (Legal)	Dr. AV Laudico (Registries)
	Restrictions	<ul style="list-style-type: none"> <li>• SC restrictive order – clarity with the use of the PI,</li> <li>• Data privacy act</li> </ul>	
Penalties		<ul style="list-style-type: none"> <li>• Absence of malice in the prohibitive acts</li> <li>• Stiff monetary fines and probation and jail time</li> </ul>	
Rules/ provisions		Clear definition of who authorizes the body that approves PI to be made available	

## 2. Open Forum

Query topic	Responses
Law focused on the data but protection of the data subject lacking	
IRR Data Privacy Act	1. Need to be pro-active; smoothly roll-out the law through – Health privacy code (DoH, DOST) <ul style="list-style-type: none"><li>• Best practices of information exchange</li><li>• Commissioner / authorized body</li></ul> 2. Self-regulation by stakeholders
Consent for PI in disease registries, biobanks	Self-regulation by stakeholders
State vs. individual re: PI	IRR?
DepEd graduate thesis and consent for studies on students (e.g. behavior)	Data privacy act
DPA effect on data mining, publicly available data	Source of data is already de-identified. Scope of DPA is process of anonymizing the data. Caution: unrelated use of PI
Effect of DPA IRR	‘Chilling effect’ has yet to be proven
Abrogation of the law/ rules (?). Can ECs allow certain research to be exempted?	Under deliberation

## B. PHREB Policies and Procedures on accreditation

(Dr. MSN Vios)

Universal principle of protection research participants	Underpins PHREB's creation
Mandates	Guidelines and requirements for EC <ol style="list-style-type: none"><li>1. review of research involving human participants</li><li>2. Management of the EC</li><li>3. Monitor conduct of the research</li></ol>
Coverage	Academe, hospitals, government agencies and consortia, clusters, site-based, health-facility-based (e.g. specialty clinic – derma, ophta)
Health, and health-related research	Impact on health of person and community
	Animal studies – IACUC Biosafety - NCBP
Indigenous communities	Level 2 and 3
Animals involved	ACUC
Biorisk and biosecurity	Biosafety - NCBP

## B. PHREB Policies and Procedures on accreditation (Dr. MSN Vios)

Accreditation	<p>Criteria-based</p> <ol style="list-style-type: none"> <li>1. Structure, function and composition</li> <li>2. Adherence to guidelines and policies</li> <li>3. Compliance to SOPs (10 core)</li> <li>4. Completeness of review-process</li> <li>5. After review process</li> <li>6. Administrative support</li> <li>7. Recording and archiving system</li> </ol>
Levels - bases	<ol style="list-style-type: none"> <li>1. Type of research</li> <li>2. Degree of risk in the research protocol (minimum</li> </ol>
Levels of accreditation	<p>1 – minimal risk</p> <p>2 – more than minimal risk; except clinical trials; post-marketing studies; functional database; part time staff</p> <p>3 – All types of registration including products for FDA registration; ICH GCP standards; functional database and fulltime staff</p>
Process	Document review, accreditors site visit
Post- accreditation	Monitoring, annual report, renewal of the certificate (q 3 yrs)
Accreditation	May be withdrawn
Enforced in 2016	Registration upon application, on-going accreditation 1-yr probation, Sanctions for non-compliance

*C. Case studies in ethics review of health social science research  
(Dr. LD de Castro)*

*We are at a crossroad with DPA but this must not hinder  
well-guided and responsible research  
(confidentiality of the data and participant's privacy)*

1. Informed consent –
  - Whose? family, community, person
  - How truthful is the information?
2. Investigator
  - Responsibility for observations in addition to the research objective
  - Respect of culture
    - Prior-consent
    - Personal information
3. Impact of the research on the community

## C. Case studies in ethics review of health social science research (Dr. LD de Castro)

- Case #1: Observations of general newborn care and provisions of care
    - Informed consent obtained from mother and healthcare giver (must include father)
    - DoH – consent from all involved
  - Investigators were instructed to just observe
  - Observations:
    - Mother used water from faucet for milk formula. *intervene?*
- *Dec of Helsinki*
    - *Consent*
    - *Interest of the participant must take precedence over all other interests*

## C. Case studies in ethics review of health social science research (Dr. LD de Castro)

- Case #2 –
  - Online survey of alcohol drinking
  - Subjects - < 18 y/o
  - Randomized – controlled
    - Treatment group – questions on drinking habits – ill effects of drinking; how to limit drinking – were given written advice on this; after 6 months, were asked on drinking habits
    - The objective of the survey was not revealed at the start; was withheld
    - *What should have been done? Would this be a cause for waiving informed consent? Disclosing full info – will this affect extent of participation*
    - A: Informed consent must be based on participant being informed; revise the method
    - Non-treatment group -
      - *Conundrum: Putting the objective in the context of research – more stringent requirement*
      - *Research for public health intervention; be upfront with the objective to the EC*

## C. Case studies in ethics review of health social science research (Dr. LD de Castro)

- Case #3 –
  - Negotiating safe-sex practices
  - Participants: female sex workers
  - Method
    - participant observation
    - Interview on practices - how, why and with whom
    - Rescued by accomplice
  - EC approved but journal reviewer declared deception was involved. Was the deception justified?
  - Giving full information – what data will be used for?
  - Where will the compromise be?

⇒ *Minimize deception; Methods of obtaining informed consent*

⇒ *Participant is benchmark on effect of the method used - If harm is not known at the start, apply the method on a small number (i.e., social preparation)*

⇒ *UNESCO guideline on social science research*

## *C. Case studies in ethics review of health social science research*

*(Dr. LD de Castro) - 4*

### Case #4 – STD research and minors

- *Responsibility in handling sensitive information that may have adverse effects on certain groups*
  - Background –
    - 27% new diagnosed 15-24 y/o;
    - 86% of STIs were MSM – 54% were age group . . .;
    - PEP + safe sex are effective in the age groups concerned
  - Issues
    - Parental permission required for certain age groups; low enrolment rate affects validity of the results
    - Parental consent?
- *Legal impediment – RH Law; Constitution*
  - *DPA*

## *D. Balancing risks and benefits in ethics review (Dr. SE Bongala)*

- Levels of risk were defined
- Assessing risk
  - Vulnerability of population
  - Types of risk
  - Scientific validity
    - Rationale
    - Objectives -> research design -> procedures
  - Investigator qualifications
- Risk/benefit ratio; subject privacy and confidentiality and protection

⇒ *Application of the ethical research principles – autonomy, justice and non-maleficence/beneficence*

⇒ *Would you recommend participation in this study? How can study be improved*

⇒ *Balance must be in favor of the participant*

## *E. Research with older persons (Dr. G Orteza)*

- National guidelines are being updated
- Rationale for research in elderly - increasing size of population and under-represented in research
- Challenges
  - Variability of health status and functional capacity
  - Decision-making process and ability to give valid informed consent
- Guidelines focus on informed consent
  - Investigator identify hindrances and use best strategy to impart information on the research
  - Cognitive assessment tools and checklists for ‘competency’
- Recommendations

⇒ *Every adult has the capacity to make decisions*

⇒ *Appreciation of risks, benefits and alternatives to the decision*

⇒ *‘Decisional capacity’ is preferred terminology - thresholds*

⇒ *Tools*

⇒ *Informed consent quiz*

⇒ *MacCAT, others (expert member in the IRB)*

## *F. Patient and family engagement (Ms. CV Auste)*

- Engagement (mutual understanding; give and take) and empowerment
- People (and family)-centered health care
  - Communication and care
  - Respect in addition to responsible and responsive services
- Capacitate patient and family to be fully engaged
- Core value of an organization
- Families are
  - untapped resources for better care and outcome
  - Key stakeholders in health care and in research
  - Experience parallels that of the patient
- Levels of engagement in research but must be from the start (e.g. conceptualizing some procedures)
- Patient (and family) -oriented research – partners, priorities, desired outcome (inclusiveness, respect, purpose, experience is part of process)
- Benefits of the engagement

- *Family – key in promotion of health and wellness of a patient; family and patient must be equally valued*
- *Research that engages family and patient => innovative and meaningful research*
- *4 keystone questions for EC e.g., interpretation of information, benefit*